Form 4: Opus Genetics Director Receives Stock for 2026 Board Service

Opus Genetics Director Jean Bennett was granted 21,127 shares of common stock as compensation for her 2026 board services.

Summary

• Jean Bennett, a Director of Opus Genetics, Inc. (IRD), acquired 21,127 shares of common stock.
• The transaction occurred on January 1, 2026.
• These shares were granted in lieu of cash for board services to be rendered in 2026.
• The number of shares was determined by dividing the aggregate retainer for board services by the average fair market value of a share of common stock the day prior to the grant date, which was $1.99 per share.
• Following this transaction, Jean Bennett beneficially owns a total of 234,652 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine insider transaction reporting a compensation grant, not a performance or strategic announcement.

Positives

• The grant of shares for 2026 board services indicates continued commitment of a director to the company.
• Compensating directors with stock aligns their interests with those of shareholders.

Negatives

• The issuance of new shares, even for compensation, can result in minor dilution for existing shareholders.

Risks

• No specific risks were detailed in this Form 4 filing, which primarily reports an insider transaction.

Future Outlook

The grant of shares for 2026 board services indicates the company's plan for continued director compensation through equity for the upcoming year.

Industry Context

This filing is a routine insider transaction report, common across all industries, reflecting a director's compensation structure. It does not provide broader industry trends or competitive analysis.

Related Party Transactions

• The grant of 21,127 shares of common stock to Director Jean Bennett in lieu of cash for board services constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Experience minor dilution due to the issuance of new shares for compensation.
• Directors: Jean Bennett's interests are further aligned with shareholders through equity compensation.

Next Steps

• Jean Bennett will continue to serve as a Director for Opus Genetics, Inc. for the 2026 period, for which these shares were granted.

Key Dates

Keywords

Opus Genetics, IRD, Form 4, Insider Transaction, Stock Grant, Director Compensation, Jean Bennett, Equity Compensation